Abstract Submission Guidelines



The Call for Abstracts is now closed.


The final decisions will be made by representatives from LMHI. Corresponding authors will be informed of the decision by 31 March, 2019.


The Scientific Committee and associated reviewer teams will review and score submissions. Abstracts will be selected on the basis of their medical and scientific significance, timeliness, quality of data and methodology, adherence to specific format requirements, and other criteria described herein.

Following review by the Scientific Committee and associated reviewers, a notice of the outcome of each abstract submitted for consideration will be sent to the presenting author listed on the abstract submission form via email. The outcome of the abstract can then be obtained directly from the website. Please note that detailed individual feedback on submissions will not be issued. The time duration allocated to presenters will be made available to successful candidates on confirmation of the acceptance of their abstracts.

If an abstract is accepted, the presenting author is expected to register for the conference within a timeframe determined by the Scientific Committee and reserve accommodation easily accessible to the conference centre at the time of the LMHI 2019. Venue suggestions are made available on www.lmhi2019.org



The Call for Abstracts is now closed.


  • Abstract submission opens: 17 September 2018
  • Deadline for submitting abstracts:
    • Priority Stream: 31 January 2019 February 9 2019
    • Late-breaking Stream*: 15 April 2019
  • Abstract outcomes:
    • Priority stream:     31 March 2019
    • Late-breaking Stream *: 15 May 2019


* Late-breaking Abstracts must be submitted via email: latebreakingabstract@lmhi2019.org

** Late-breaking abstracts refer to important current research considered to be of particular interest for the homeopathic community. Late-breaking abstracts will undergo formal peer-review evaluation by the Scientific Committee.



Interested authors may register for an account on www.lmhi2019.org and then log in and under “Call for Abstracts” – “Submit Abstract” submit the relevant documentation. Please ensure CAPS LOCK is switched off when submitting abstracts.

Outcomes for priority abstract submissions will be completed by 31 March 2019. Please be sure to check your spam/junk folder in case the e-mail is delivered there, or log on and click “Abstracts”. If you have questions, please contact us.



The person who makes the abstract submission is considered to be the presenting author and is responsible for the following:


  • Undertaking to present the abstract for oral or poster presentation, if accepted.
  • Assuring that financial relationships with commercial entities have been disclosed for self, spouse, and institution.
  • Assuring that if the presenting author is replaced with a new presenter, the new presenter will disclose financial relationships with commercial entities for self, spouse, and institution.  The final abstract submission must include disclosure information for the author who will present at LMHI 2019.
  • Providing complete and accurate contact and affiliation information for ALL co-authors; correct e-mail addresses are essential.
  • Assuring that ALL co-authors have reviewed and approved the abstract’s content.
  • Providing an electronic version of a poster abstract. Poster room credentials will not be issued until electronic versions of posters have been received.
  • Assuring that all Terms and Conditions (as stipulated) have been adhered to.
  • Assuming responsibility to ensure that the article has all necessary approvals by patients in case of Clinical Trials.




  • Previous Submission, Publication, or Presentation of Data or Abstract
  • The LMHI 2019 Scientific Committee seeks to accept work that has not been previously published or publicly presented. Consideration may be given to a previously presented submission if meaningful newer data or different analyses are included. If your study data or abstract information has been published, submitted for publication where publication is anticipated on or before 30 September 2019, or presented at any other major national or international scientific or medical conference (i.e. 300 or more attendees), you will be asked to provide details on the previous presentation or publication. These details are to include name and year of prior conference, publication information or submission for publication, and whether the prior abstract is copyrighted.
  • Abstract text that is under copyright by a publication or conference should not be submitted verbatim to LMHI 2019. In addition, you may be asked which data have been updated for presentation at LMHI 2019.



Abstracts must be submitted via the website

Submissions forwarded by e-mail, fax, post or courier will not be accepted.



Choose the most suitable and relevant topic from the established list of LMHI topic categories. Please keep in mind that, on review of the abstract, the Scientific Committee and external reviewers may elect to assign an abstract to a topic deemed more appropriate.


Abstracts can be assigned to one of the following topics:


  1. Cultural background
  2. Preclinic Research
  3. Agro-Homeopathy
  4. Provings
  5. Clinical Research
  6. Clinical Methodology
  7. Veterinary
  8. Dentistry
  9. Pharmacy
  10. Communication
  11. Integration within NHS



The abstract title should be concise and clearly convey the subject of the abstract.


  • Maximum length: 100 characters, including spaces
  • Style: Titles should be in all upper case letters



Author’s Names

Include the name (name and surname), email address, and institutional affiliation for co-authors. Up to 10 may be entered (no exceptions). If there are more than 10 authors, you may use the final (10th) slot to name a study group that represents those who cannot be listed individually or indicate “et al.“. Please DO NOT enter the names of additional individual authors that exceed the maximum number of 10 individual authors.


Enter the primary affiliation for each author.  Please spell out the full name of the institution and do not use abbreviations such as “Univ.” for “University.”


Changes in Presenting Author
The author noted as the presenting author on an abstract is responsible for delivering either the oral or poster presentation if the abstract is accepted. In case of an emergency, an alternate may take the presenting author’s place. The new presenting author must update the abstract submission to disclose information for the new presenter, his or her spouse, and institution. The new presenter must be listed as co-author on the abstract and must be registered and accepted for attendance at LMHI 2019.


Disclosure of financial relationships with commercial entities is required for the following:


  • Presenting author or other authors




  • Trade names, brand names or other proprietary names should not be used in abstracts.
  • Maximum length: Up to 5000 characters, cumulative, including spaces
  • Section Heads: Bold

The layout of any abstract should conform to the section heads described below.
Section heads (i.e., Background, Materials and Methods, Results, and Conclusion and Keywords), are included in the abstract body character count.


Briefly and clearly describe the hypothesis of the study. Why was the study conducted?


Materials and Methods
Detail the experimental methods and processes employed in the study. What did you do?


Describe the precise findings of the study; promises of results “to be determined” are not acceptable. Describe what you found and include data.


Conclusion and Keywords
Describe logically sound conclusions and reliable inferences drawn from the study results. Why are the study’s findings important?


Abstracts Describing Clinical Trials
If an abstract is reporting data from clinical trials of human subjects, describe study design (e.g., prospective, randomised, double-blind) and population (i.e., numbers enrolled and demographics). The presenting author should have been involved in the gathering of the raw data and be able to discuss the analysis. Please also include the following information:


  • Details of requisite ethical clearance.
  • Is the study ongoing or completed?
  • Are the results final or preliminary?
  • Describe statistical analyses employed, including those used to support the results.


Two keywords are required; up to 5 are allowed.


Notification of Abstract Disposition

After the Scientific Committee and external expert reviewers complete the review and scores all abstracts submitted for consideration, the author and co-authors for whom correct e-mail addresses have been provided will be sent e-mail notification of the review outcome.




  • Subject matter is not appropriate for LMHI 2019.
  • Abstract is duplicative of other submissions.
  • Format does not follow guidelines (e.g., section[s] missing).
  • Submission is written poorly.
  • Background does not summarize the hypothesis.
  • Methodology is inadequate or insufficient to support conclusions.
  • Controls are absent or inadequate.
  • Statistical evaluation is inadequate or absent.
  • Summary of essential results is inadequate or absent.
  • Data are not included, or offer inadequate/insufficient support for conclusions.
  • The submission reports clinical trial data from: unplanned analysis, or incomplete / ongoing studies.



In line with the stipulated Terms and Conditions of the submission of content and by submitting your abstract to the LMHI 2019, you hereby authorise the LMHI 2019 to use the submitted information in printed / electronic format related to the promotion or conduct of LMHI 2019.

The contents of the LMHI 2019 Program and related Abstracts publication are protected by copyright. We require that permission to replicate or reproduce any part of an abstract produced in relation to the LMHI 2019 be obtained from the LMHI 2019 Secretariat; however, study data are the property of the author(s) or study sponsors as relevant.

No Comments